Groups
Company Size (Fulltime employees)
Looking for
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

Rius Medical UG (Haftungsbeschränkt) Germany

About Rius Medical: Rius Medical is designing and developing a new generation of Commercial cell therapies positioned at the crossroads of two high-potential programs: (1.) genetically engineering red blood cells for an entirely new class of cellular medicines and (2.) potent NK-cell therapy products. Due to their mechanism of action, engineered red blood cells demonstrated treatments for wide range of patients from starving cancer cells to targeting autoimmune diseases. Building on exceptional progress in cell therapies, Rius Medical is in a unique position to offer Third-Generation red blood cells for drug delivery that addresses Rare Diseases, Oncology and Autoimmune Diseases like type 1 diabetes! Furthermore, harnessing the unique power of natural killer (NK) cells enables the treatment of cancer and infectious diseases such as Influenza virus or SARS-Coronavirus (i.e. COVID-19 pandemic). That’s right, NK-cells as vaccine delivery NOT for antibodies but for “memory T cells” activation!
Website:
https://ec.europa.eu/eipp/desktop/en/projects/project-11851.html
Company Size (Fulltime employees)
1-10
Year of foundation
2016
Looking for
Please specify your partnering goal
Bring together technology & funds for improving “China Focus” healthcare situation on an equal basis.
Funding Status
Seeking investors for Series A
Now raising (In USD)
1,665,454 USD
Headquartner in China
No
Plan in China
Rius Medical unique position as CDMO (contract development and manufacturing organization) is not limited to drug delivery. Yes, drug delivery programs bring EUR 130 million revenue sooner than “Rius Medical’s blood transfusion” program. However, Rius Medical’s path to becoming a market leader in healthcare in promoting excellence, innovation and good business practices, is driven by its “blood transfusion” program. The Plan in China is local Jobs in China for manufacturing of stem cells derived “blood transfusion” products. Also drug delivery via "Third-Generation red blood cells for drug delivery" that addresses Rare Diseases, Oncology and Autoimmune Diseases like type 1 diabetes, is region-specific; as in Europe, USA and China regions due to ABO blood group and other antigens being region-specific!
Biotech/Pharma Category
Assets Information 1: Name|Description|Indications|Stage|IP countries
eRBC|Red Blood Cells for Drug Delivery|Oncology|Prototype Assembly|N/A
Biotech/Pharma Asset Stage
Mr Denis Demarais
Mr Denis Demarais
LinkedIn logo Founder and CEO 
Functionality
Management

Simcere Pharmaceutical Group China

We are rapidly transitioning to an innovation and R&D driven Pharmaceutical company, leveraging our leading manufacturing and commercial capabilities to achieve our mission of “providing today' s patients with medicines of the future“ We have been continuously recognized as one of the “Top 10 Innovative Pharmaceutical Enterprises in China” 1 and “Top 100 Pharmaceutical Manufacturing Enterprises of China”

Website:
www.simcere.com
Looking for
Please specify your partnering goal
Licensing
Headquartner in China
Yes
Biotech/Pharma Category
Wayne Yin
BD Director 
Functionality
Investment

WPD Pharmaceuticals Canada

WPD has 8 novel drug candidates with 4 that are in clinical development stage and 4 in pre-clinical development. These drug candidates were researched at institutions including the Mayo Clinic and Emory University, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.

Alongside direct investment of $60 million, over $29 million of grant funding (total of $89 million USD) has gone towards the development of our robust drug development pipeline with a focus on melanoma, brain cancer, leukemia, and pancreatic cancer. Notably, these funds do not include $14 million USD in grants recently awarded to WPD Pharmaceuticals from The National Centre for Research and Development in Poland.

With a groundswell of multi-continental grant support and a diverse portfolio of breakthrough drug technologies, WPD Pharmaceuticals is now strategically positioned to enter the market with blockbuster potential.

Website:
https://www.wpdpharmaceuticals.com/about/overview/
Company Size (Fulltime employees)
11-50
Year of foundation
2017
Stock Market and Ticker/Symbol/Number
WCSE: BIO
Looking for
Please specify your partnering goal
We are looking for investors and partners for co-develop our product in China and co-develop partner product in EU.
Now raising (In USD)
between $ 3 million - $10 million
Headquartner in China
No
Plan in China
We are looking for investors and partners for co-develop our product in China and co-develop partner product in EU.
Biotech/Pharma Category
Investment Focus
Seeking funding to move from pre clinical stage to Phase 1/2 clinical trial and support co-development in EU
Mariusz Olejniczak
CEO 
Functionality
Management